Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Sep 2;64(3):449–456. doi: 10.1136/ard.2004.023572

A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis

L Lohmander 1, D McKeith 1, O Svensson 1, M Malmenas 1, L Bolin 1, A Kalla 1, G Genti 1, J Szechinski 1, C Ramos-Remus 1, t for 1
PMCID: PMC1755403  PMID: 15345500

Abstract

Objective: To evaluate the gastrointestinal safety and efficacy of the COX inhibiting nitric oxide donator AZD3582 in patients with hip or knee osteoarthritis.

Methods: 970 patients were randomised (7:7:2) to AZD3582 750 mg twice daily, naproxen 500 mg twice daily, or placebo twice daily in a double blind study. The primary end point was the six week incidence of endoscopic gastroduodenal ulcers (diameter ⩾3 mm). Overall damage measured on the Lanza scale was a secondary end point. Safety and tolerability assessments included endoscopic upper gastrointestinal erosions and the gastrointestinal symptom rating scale (GSRS). Efficacy was primarily assessed by WOMAC.

Results: The incidence of ulcers with AZD3582 was 9.7% and with naproxen 13.7% (p = 0.07, NS), v 0% on placebo. The incidence of Lanza scores >2 was higher with naproxen (43.7%) than with AZD3582 (32.2%) (p<0.001). Compared with baseline, significantly fewer ulcers and erosions developed in stomach and stomach/duodenum combined, and fewer erosions developed in stomach, duodenum, and both combined on AZD3582 than on naproxen. GSRS reflux and abdominal pain subscale scores were lower for AZD3582 than for naproxen but there was no difference for indigestion, constipation, and diarrhoea. AZD3582 was as effective as naproxen at improving WOMAC scores. Both agents were well tolerated, with no significant effects on blood pressure.

Conclusions: At doses with similar efficacy in relieving osteoarthritis symptoms, the primary end point of six week endoscopic gastroduodenal ulcer incidence was not significantly different between AZD3582 and naproxen. Most secondary endoscopic gastrointestinal end points favoured AZD3582.

Full Text

The Full Text of this article is available as a PDF (105.9 KB).

Figure 1.

Figure 1

Open in a new tab

 Patient disposition in a six week placebo controlled trial of the gastrointestinal safety and efficacy of AZD3582 and naproxen in patients with osteoarthritis.

Figure 2.

Figure 2

Open in a new tab

 Incidence and location of ulcers ⩾3 mm or ⩾5 mm (with depth) in osteoarthritic patients treated with AZD3582 or naproxen.

Figure 3.

Figure 3

Open in a new tab

 Mean supine systolic blood pressure in patients with osteoarthritis receiving AZD3582, naproxen, or placebo. Error bars = SD.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agrawal N. M., Caldwell J., Kivitz A. J., Weaver A. L., Bocanegra T. S., Ball J., Dhadda S., Hurley S., Hancock L. Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Clin Ther. 1999 Apr;21(4):659–674. doi: 10.1016/s0149-2918(00)88318-6. [DOI] [PubMed] [Google Scholar]
  2. Bellamy N., Buchanan W. W., Goldsmith C. H., Campbell J., Stitt L. W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988 Dec;15(12):1833–1840. [PubMed] [Google Scholar]
  3. Berndt Georg, Grosser Nina, Hoogstraate Janet, Schröder Henning. A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate. Eur J Pharm Sci. 2004 Feb;21(2-3):331–335. doi: 10.1016/j.ejps.2003.10.020. [DOI] [PubMed] [Google Scholar]
  4. Bjarnason I., Macpherson A., Rotman H., Schupp J., Hayllar J. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen. Scand J Gastroenterol. 1997 Feb;32(2):126–130. doi: 10.3109/00365529709000182. [DOI] [PubMed] [Google Scholar]
  5. Davies N. M., Røseth A. G., Appleyard C. B., McKnight W., Del Soldato P., Calignano A., Cirino G., Wallace J. L. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther. 1997 Feb;11(1):69–79. doi: 10.1046/j.1365-2036.1997.115286000.x. [DOI] [PubMed] [Google Scholar]
  6. Emery P., Zeidler H., Kvien T. K., Guslandi M., Naudin R., Stead H., Verburg K. M., Isakson P. C., Hubbard R. C., Geis G. S. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999 Dec 18;354(9196):2106–2111. doi: 10.1016/S0140-6736(99)02332-6. [DOI] [PubMed] [Google Scholar]
  7. Fiorucci S., Antonelli E., Burgaud J. L., Morelli A. Nitric oxide-releasing NSAIDs: a review of their current status. Drug Saf. 2001;24(11):801–811. doi: 10.2165/00002018-200124110-00002. [DOI] [PubMed] [Google Scholar]
  8. Fries J. F., Miller S. R., Spitz P. W., Williams C. A., Hubert H. B., Bloch D. A. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):647–655. doi: 10.1016/s0016-5085(89)80061-7. [DOI] [PubMed] [Google Scholar]
  9. Goldstein J. L., Correa P., Zhao W. W., Burr A. M., Hubbard R. C., Verburg K. M., Geis G. S. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol. 2001 Apr;96(4):1019–1027. doi: 10.1111/j.1572-0241.2001.03740.x. [DOI] [PubMed] [Google Scholar]
  10. Hawkey C. J., Jones J. I., Atherton C. T., Skelly M. M., Bebb J. R., Fagerholm U., Jonzon B., Karlsson P., Bjarnason I. T. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut. 2003 Nov;52(11):1537–1542. doi: 10.1136/gut.52.11.1537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hawkey C. J., Laine L., Harper S. E., Quan H. U., Bolognese J. A., Mortensen E., Rofecoxib Osteoarthritis Endoscopy Multinational Study Group Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther. 2001 Oct;15(10):1593–1601. doi: 10.1046/j.1365-2036.2001.01007.x. [DOI] [PubMed] [Google Scholar]
  12. Hawkey C. J., Langman M. J. S. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut. 2003 Apr;52(4):600–608. doi: 10.1136/gut.52.4.600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hawkey C. J. NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist's perspective. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S23–S30. [PubMed] [Google Scholar]
  14. Hawkey C., Laine L., Simon T., Beaulieu A., Maldonado-Cocco J., Acevedo E., Shahane A., Quan H., Bolognese J., Mortensen E. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum. 2000 Feb;43(2):370–377. doi: 10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  15. Hudson N., Taha A. S., Russell R. I., Trye P., Cottrell J., Mann S. G., Swanell A. J., Sturrock R. D., Hawkey C. J. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology. 1997 Jun;112(6):1817–1822. doi: 10.1053/gast.1997.v112.pm9178671. [DOI] [PubMed] [Google Scholar]
  16. Hunt R. H., Harper S., Callegari P., Yu C., Quan H., Evans J., James C., Bowen B., Rashid F. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther. 2003 Jan;17(2):201–210. doi: 10.1046/j.1365-2036.2003.01407.x. [DOI] [PubMed] [Google Scholar]
  17. Kivitz Alan, Eisen Glenn, Zhao William W., Bevirt Terry, Recker David P. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract. 2002 Jun;51(6):530–537. [PubMed] [Google Scholar]
  18. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001 Feb;120(3):594–606. doi: 10.1053/gast.2001.21907. [DOI] [PubMed] [Google Scholar]
  19. Laine L., Harper S., Simon T., Bath R., Johanson J., Schwartz H., Stern S., Quan H., Bolognese J. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology. 1999 Oct;117(4):776–783. doi: 10.1016/s0016-5085(99)70334-3. [DOI] [PubMed] [Google Scholar]
  20. Lanas A., Bajador E., Serrano P., Fuentes J., Carreño S., Guardia J., Sanz M., Montoro M., Sáinz R. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000 Sep 21;343(12):834–839. doi: 10.1056/NEJM200009213431202. [DOI] [PubMed] [Google Scholar]
  21. Lanza F. L., Graham D. Y., Davis R. E., Rack M. F. Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method. Dig Dis Sci. 1990 Dec;35(12):1494–1499. doi: 10.1007/BF01540567. [DOI] [PubMed] [Google Scholar]
  22. Lanza F. L., Rack M. F., Simon T. J., Quan H., Bolognese J. A., Hoover M. E., Wilson F. R., Harper S. E. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther. 1999 Jun;13(6):761–767. doi: 10.1046/j.1365-2036.1999.00529.x. [DOI] [PubMed] [Google Scholar]
  23. Muscará M. N., McKnight W., Del Soldato P., Wallace J. L. Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sci. 1998;62(15):PL235–PL240. doi: 10.1016/s0024-3205(98)00072-1. [DOI] [PubMed] [Google Scholar]
  24. Pendleton A., Arden N., Dougados M., Doherty M., Bannwarth B., Bijlsma J. W., Cluzeau F., Cooper C., Dieppe P. A., Günther K. P. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2000 Dec;59(12):936–944. doi: 10.1136/ard.59.12.936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Simon L. S., Weaver A. L., Graham D. Y., Kivitz A. J., Lipsky P. E., Hubbard R. C., Isakson P. C., Verburg K. M., Yu S. S., Zhao W. W. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999 Nov 24;282(20):1921–1928. doi: 10.1001/jama.282.20.1921. [DOI] [PubMed] [Google Scholar]
  26. Singh G., Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl. 1999 Apr;56:18–24. [PubMed] [Google Scholar]
  27. Svedlund J., Sjödin I., Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988 Feb;33(2):129–134. doi: 10.1007/BF01535722. [DOI] [PubMed] [Google Scholar]
  28. Talley N. J., Fullerton S., Junghard O., Wiklund I. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol. 2001 Jul;96(7):1998–2004. doi: 10.1111/j.1572-0241.2001.03932.x. [DOI] [PubMed] [Google Scholar]
  29. Talley N. J., Meineche-Schmidt V., Paré P., Duckworth M., Räisänen P., Pap A., Kordecki H., Schmid V. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther. 1998 Nov;12(11):1055–1065. doi: 10.1046/j.1365-2036.1998.00410.x. [DOI] [PubMed] [Google Scholar]
  30. Wallace J. L. Cooperative modulation of gastrointestinal mucosal defence by prostaglandins and nitric oxide. Clin Invest Med. 1996 Oct;19(5):346–351. [PubMed] [Google Scholar]
  31. Wallace J. L., McKnight W., Reuter B. K., Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 2000 Sep;119(3):706–714. doi: 10.1053/gast.2000.16510. [DOI] [PubMed] [Google Scholar]
  32. Ware J. E., Jr, Sherbourne C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473–483. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES